| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Vofopitant targets the neurokinin 1 (NK1) receptor, which is involved in modulating stress, anxiety, and pain responses by binding to the neuropeptide substance P. As a potent NK1 receptor antagonist, it blocks the binding of substance P to the NK1 receptor, thereby modulating stress, anxiety, and emetic responses.
|
|---|---|
| ln Vitro |
Vofopitant is a strong antagonist of the tachykinin NK1 receptor, having pKs of 10.6, 9.5, and 9.8 for NK1 receptors in rats, humans, and ferrets, respectively. With pKs of 6.3, 6.6, 6.5, and 6.5, respectively, volopitant has mild inhibitory effects on rat 5-HT1A, bovine 5-HT1D, rat 5-HT2A, rat histamine H1, and guinea pig histamine H2. 6.6 as well as 5.6. Vofopitant exhibits a minimal affinity of pIC50 <5.0 for both NK2 and NK3[1]. GR205171 (300 µM) suppresses paroxetine-induced increases in [5-HT]ext in the dorsal raphe nucleus and amplifies the effects of paroxetine on cortical [5-HT]ext [3].
In vitro, Vofopitant is a potent tachykinin NK1 receptor antagonist with pKi values of 10.6, 9.5, and 9.8 for human, rat, and ferret NK1 receptors, respectively. It also has pKi values of 6.3 for other receptors. Its activity is assessed using receptor binding assays measuring displacement of radiolabeled substance P. |
| ln Vivo |
In the T-maze, vofopitant (GR205171, 30 mg/kg, subcutaneous injection) expands the options for a 25-second delayed reward [2]. When paroxetine is administered to wild-type mice, the frontal cortex of those mice experiences an increase in extracellular 5-HT levels; however, this effect is not observed in wild-type mice or paroxetine-treated NK1 receptor knockout mice [3].
In vivo, Vofopitant has anxiolytic and antiemetic activity. It has been studied for the treatment of post-traumatic stress disorder (PTSD). It exhibits potent broad-spectrum anti-emetic activity. |
| Enzyme Assay |
In vitro receptor binding assays for Vofopitant are performed using membrane preparations expressing human, rat, or ferret NK1 receptors. Radioligand competition binding assays using [³H]-substance P are used to measure the compound's affinity for NK1 receptors. pKi values are calculated from competition curves.
|
| Cell Assay |
In vitro cellular assays for Vofopitant are performed using cells expressing NK1 receptors. Cells are treated with substance P in the presence of increasing concentrations of the compound. Calcium mobilization or other signaling pathways downstream of NK1 receptor activation are measured. The inhibition of substance P-induced signaling is quantified.
|
| Animal Protocol |
In vivo animal experiments for Vofopitant are conducted in rodent models of anxiety or emesis. A typical protocol involves administration of the compound via oral or intraperitoneal routes, followed by assessment of anxiety-like behavior in the elevated plus maze or conditioned fear paradigms. Antiemetic activity is evaluated in models of emesis.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Vofopitant have been characterized in part. The compound has a molecular weight of 462.43 and molecular formula C₂₂H₂₅F₃N₆O. It is a potent NK1 receptor antagonist. Further PK details, including half-life, bioavailability, and tissue distribution, are available from the manufacturer's data sheets.
|
| Toxicity/Toxicokinetics |
Toxicological data for Vofopitant are not extensively reported. As a research-use compound, its safety profile has not been formally evaluated in comprehensive preclinical toxicology studies. The compound is intended for research purposes only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
|
| Additional Infomation |
Vofopitant has been used in research trials to treat PTSD, primary insomnia, and sleep initiation and maintenance disorders.
Vofopitant is also known as GR 205171. It is a potent NK1 receptor antagonist with pKi values of 10.6, 9.5, and 9.8 for human, rat, and ferret NK1 receptors, respectively. It has anxiolytic and antiemetic activity and has been studied for PTSD. This product is for research use only. |
| Molecular Formula |
C21H23N6OF3
|
|---|---|
| Molecular Weight |
432.44212
|
| Exact Mass |
432.189
|
| Elemental Analysis |
C, 58.33; H, 5.36; F, 13.18; N, 19.43; O, 3.70
|
| CAS # |
168266-90-8
|
| Related CAS # |
Vofopitant dihydrochloride;168266-51-1;rac-Vofopitant-d3
|
| PubChem CID |
6918331
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.39g/cm3
|
| Boiling Point |
542.5ºC at 760 mmHg
|
| Flash Point |
281.9ºC
|
| Vapour Pressure |
7.83E-12mmHg at 25°C
|
| Index of Refraction |
1.624
|
| LogP |
3.992
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
31
|
| Complexity |
562
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
COC1=C(C=C(C=C1)N2C(=NN=N2)C(F)(F)F)CN[C@H]3CCCN[C@H]3C4=CC=CC=C4
|
| InChi Key |
XILNRORTJVDYRH-HKUYNNGSSA-N
|
| InChi Code |
InChI=1S/C21H23F3N6O/c1-31-18-10-9-16(30-20(21(22,23)24)27-28-29-30)12-15(18)13-26-17-8-5-11-25-19(17)14-6-3-2-4-7-14/h2-4,6-7,9-10,12,17,19,25-26H,5,8,11,13H2,1H3/t17-,19-/m0/s1
|
| Chemical Name |
(2S,3S)-N-[[2-methoxy-5-[5-(trifluoromethyl)tetrazol-1-yl]phenyl]methyl]-2-phenylpiperidin-3-amine
|
| Synonyms |
Vofopitant; 168266-90-8; GR-205,171; GR205171; GR205,171; GR-205171; GR 205,171; GR-205171; GR205171; GR 205171; K08BK043YS;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3125 mL | 11.5623 mL | 23.1246 mL | |
| 5 mM | 0.4625 mL | 2.3125 mL | 4.6249 mL | |
| 10 mM | 0.2312 mL | 1.1562 mL | 2.3125 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
